Paul Whitelock
Psychiatry · San Marcos, TXNPI 1497764385
Payments from drug & device makers
Across 290 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$603
- Lundbeck LLC$598
- Alkermes, Inc.$237
- Sunovion Pharmaceuticals Inc.$147
- plus $614 from 13 others
What the payments were for
- Food & beverage$4,42099%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,239 |
| Otsuka America Pharmaceutical, Inc. | 58 | $1,033 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $603 |
| Lundbeck LLC | 40 | $598 |
| Alkermes, Inc. | 9 | $237 |
| Sunovion Pharmaceuticals Inc. | 16 | $147 |
| Vanda Pharmaceuticals Inc. | 7 | $132 |
| Tris Pharma Inc | 7 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Noven Therapeutics, LLC | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Corium, LLC | 2 | $30 |
| Indivior Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$100
How this compares
$4,471 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 49 | $80,642 |
| TrintellixVortioxetine Hydrobromide | 60 | $32,251 |
| VraylarCariprazine Hcl | 11 | $14,400 |
| EntrestoSacubitril/Valsartan | 12 | $8,081 |
| FarxigaDapagliflozin Propanediol | 12 | $6,839 |
| Lisdexamfetamine Dimesylate | 41 | $6,529 |
| Paliperidone ErPaliperidone | 21 | $5,541 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,425 |
| Quetiapine Fumarate | 233 | $4,181 |
| Aripiprazole | 136 | $3,743 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 83 | $3,522 |
| Lurasidone Hcl | 33 | $3,135 |
| Lamotrigine | 195 | $2,735 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 47 | $2,049 |
| Gabapentin | 124 | $1,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,033 | $80,64249 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $102 | $36,67672 claims |
| AbbVieVraylar | $1,239 | $14,40011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in San Marcos
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.